Figure 1 | British Journal of Cancer

Figure 1

From: Evaluation of a chemoresponse assay as a predictive marker in the treatment of recurrent ovarian cancer: further analysis of a prospective study

Figure 1

Association of clinical treatment assay result (match) with PFS. Patients treated with assay-sensitive treatments experienced a median PFS of 8.8 months, whereas those treated with assay-non-sensitive treatments experienced a median PFS of 5.9 months. Reproduced by kind permission of Elsevier from Rutherford et al (2013).

Back to article page